Cargando…

Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines

Background: The pathophysiology underlying altered blood-cerebrospinal fluid barrier (BCSFB) function in Alzheimer's disease (AD) is unknown but may relate to endothelial cell activation and cytokine mediated inflammation. Methods: Cerebrospinal fluid (CSF) and peripheral blood were concurrentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, Brian R., Jones, Richard N., Daiello, Lori A., de la Monte, Suzanne M., Stopa, Edward G., Johanson, Conrad E., Denby, Charles, Grammas, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110816/
https://www.ncbi.nlm.nih.gov/pubmed/30186149
http://dx.doi.org/10.3389/fnagi.2018.00245
_version_ 1783350543555493888
author Ott, Brian R.
Jones, Richard N.
Daiello, Lori A.
de la Monte, Suzanne M.
Stopa, Edward G.
Johanson, Conrad E.
Denby, Charles
Grammas, Paula
author_facet Ott, Brian R.
Jones, Richard N.
Daiello, Lori A.
de la Monte, Suzanne M.
Stopa, Edward G.
Johanson, Conrad E.
Denby, Charles
Grammas, Paula
author_sort Ott, Brian R.
collection PubMed
description Background: The pathophysiology underlying altered blood-cerebrospinal fluid barrier (BCSFB) function in Alzheimer's disease (AD) is unknown but may relate to endothelial cell activation and cytokine mediated inflammation. Methods: Cerebrospinal fluid (CSF) and peripheral blood were concurrently collected from cognitively healthy controls (N = 21) and patients with mild cognitive impairment (MCI) (N = 8) or AD (N = 11). The paired serum and CSF samples were assayed for a panel of cytokines, chemokines, and related trophic factors using multiplex ELISAs. Dominance analysis models were conducted to determine the relative importance of the inflammatory factors in relationship to BCSFB permeability, as measured by CSF/serum ratios for urea, creatinine, and albumin. Results: BCSFB disruption to urea, a small molecule distributed by passive diffusion, had a full model coefficient of determination (r(2)) = 0.35, and large standardized dominance weights (>0.1) for monocyte chemoattractant protein-1, interleukin (IL)-15, IL-1rα, and IL-2 in serum. BCSFB disruption to creatinine, a larger molecule governed by active transport, had a full model r(2) = 0.78, and large standardized dominance weights for monocyte inhibitor protein-1b in CSF and tumor necrosis factor-α in serum. BCSFB disruption to albumin, a much larger molecule, had a full model r(2) = 0.62, and large standardized dominance weights for IL-17a, interferon-gamma, IL-2, and VEGF in CSF, as well IL-4 in serum. Conclusions: Inflammatory proteins have been widely documented in the AD brain. The results of the current study suggest that changes in BCSFB function resulting in altered permeability and transport are related to expression of specific inflammatory proteins, and that the shifting distribution of these proteins from serum to CSF in AD and MCI is correlated with more severe perturbations in BCSFB function.
format Online
Article
Text
id pubmed-6110816
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61108162018-09-05 Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines Ott, Brian R. Jones, Richard N. Daiello, Lori A. de la Monte, Suzanne M. Stopa, Edward G. Johanson, Conrad E. Denby, Charles Grammas, Paula Front Aging Neurosci Neuroscience Background: The pathophysiology underlying altered blood-cerebrospinal fluid barrier (BCSFB) function in Alzheimer's disease (AD) is unknown but may relate to endothelial cell activation and cytokine mediated inflammation. Methods: Cerebrospinal fluid (CSF) and peripheral blood were concurrently collected from cognitively healthy controls (N = 21) and patients with mild cognitive impairment (MCI) (N = 8) or AD (N = 11). The paired serum and CSF samples were assayed for a panel of cytokines, chemokines, and related trophic factors using multiplex ELISAs. Dominance analysis models were conducted to determine the relative importance of the inflammatory factors in relationship to BCSFB permeability, as measured by CSF/serum ratios for urea, creatinine, and albumin. Results: BCSFB disruption to urea, a small molecule distributed by passive diffusion, had a full model coefficient of determination (r(2)) = 0.35, and large standardized dominance weights (>0.1) for monocyte chemoattractant protein-1, interleukin (IL)-15, IL-1rα, and IL-2 in serum. BCSFB disruption to creatinine, a larger molecule governed by active transport, had a full model r(2) = 0.78, and large standardized dominance weights for monocyte inhibitor protein-1b in CSF and tumor necrosis factor-α in serum. BCSFB disruption to albumin, a much larger molecule, had a full model r(2) = 0.62, and large standardized dominance weights for IL-17a, interferon-gamma, IL-2, and VEGF in CSF, as well IL-4 in serum. Conclusions: Inflammatory proteins have been widely documented in the AD brain. The results of the current study suggest that changes in BCSFB function resulting in altered permeability and transport are related to expression of specific inflammatory proteins, and that the shifting distribution of these proteins from serum to CSF in AD and MCI is correlated with more severe perturbations in BCSFB function. Frontiers Media S.A. 2018-08-21 /pmc/articles/PMC6110816/ /pubmed/30186149 http://dx.doi.org/10.3389/fnagi.2018.00245 Text en Copyright © 2018 Ott, Jones, Daiello, de la Monte, Stopa, Johanson, Denby and Grammas. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Ott, Brian R.
Jones, Richard N.
Daiello, Lori A.
de la Monte, Suzanne M.
Stopa, Edward G.
Johanson, Conrad E.
Denby, Charles
Grammas, Paula
Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title_full Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title_fullStr Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title_full_unstemmed Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title_short Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
title_sort blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and alzheimer's disease: relationship to inflammatory cytokines and chemokines
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110816/
https://www.ncbi.nlm.nih.gov/pubmed/30186149
http://dx.doi.org/10.3389/fnagi.2018.00245
work_keys_str_mv AT ottbrianr bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT jonesrichardn bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT daielloloria bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT delamontesuzannem bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT stopaedwardg bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT johansonconrade bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT denbycharles bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines
AT grammaspaula bloodcerebrospinalfluidbarriergradientsinmildcognitiveimpairmentandalzheimersdiseaserelationshiptoinflammatorycytokinesandchemokines